Increasing Prevalence of Alopecia and R&D of New Therapies to Augment Growth of Androgenetic Alopecia Treatment Market
Increasing prevalence of alopecia is expected to propel growth of the androgenetic alopecia market. For instance, according to a 2019 survey released by the China Association of Health Promotion and Education (CAHEP), one out of six Chinese people, or about 250 million people, are suffering from hair loss. R&D of new therapies is expected to offer lucrative growth opportunities for players in the global androgenetic alopecia treatment market . For instance, in February 2021, Histogen Inc. announced that the company’s Phase 1b/2a clinical trial of HST-001 or hair stimulating complex, which is intended to be a physician-administered therapeutic for hair loss, demonstrated significant change from baseline in total hairs (terminal and vellus) in the target area. Moreover, adoption of stem cell therapy is also expected to aid in growth of the market. For instance, in May 2020, researchers from MEDIPOST Co., Ltd. and Chung-Ang University College of Medicine, South Korea, Primed ...